Physician profile
Thomas Digeronimo
NPI 1134102973
$22,970.41
in general payments reported to CMS, 2019-2025
70 companies · $3,494 in 2025
The $3,494 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,773 · 2020: $2,889 · 2021: $4,226 · 2022: $3,427 · 2023: $2,768 · 2024: $3,394 · 2025: $3,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,556 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,555.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,948.69 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,748.86 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,489.92 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,456.20 | 2019-2025 | |
| Amgen INC. | $1,406.86 | 2019-2025 | Aimovig, Uplizna |
| Pfizer INC. | $1,303.99 | 2019-2025 | |
| Celgene Corporation | $867.07 | 2020-2025 | Zeposia |
| Eisai INC. | $739.95 | 2020-2025 | |
| Emd Serono, INC. | $724.24 | 2019-2025 | Mavenclad |
| Allergan, INC. | $715.71 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $693.61 | 2019-2023 | |
| Lilly USA, LLC | $519.89 | 2019-2025 | Kisunla, Emgality |
| Avanir Pharmaceuticals, INC. | $470.40 | 2019-2022 | |
| Lundbeck LLC | $431.79 | 2020-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $430.88 | 2020-2025 | Valtoco |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Digeronimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.